Improving influenza vaccines by targeting both variable and conserved antigens
Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens
This study is looking at a new way to make flu vaccines better by using a special DNA vaccine that targets different parts of the virus, which could help protect you from more flu strains and keep you healthier during flu season.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Orlance, INC. NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11008800 on NIH RePORTER |
What this research studies
This research aims to enhance the effectiveness of seasonal influenza vaccines by combining a DNA vaccine that targets both variable and conserved antigens. By doing so, the approach seeks to provide a more precise match to circulating virus strains, which can change from year to year. The study will explore how this dual-target strategy can improve immune responses and potentially offer broader protection against various influenza strains, including those that may cause pandemics. Patients may benefit from a more effective vaccine that reduces the risk of severe illness and hospitalization.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at higher risk for influenza complications, such as the elderly and those with underlying health conditions.
Not a fit: Patients who are not at risk for influenza or those who have already received a seasonal vaccine may not receive significant benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective influenza vaccine that provides better protection against seasonal and pandemic strains.
How similar studies have performed: Other research has shown promise in developing universal influenza vaccines, indicating that this approach has potential for success.
Where this research is happening
Seattle, United States
- Orlance, INC. — Seattle, United States (Active)
Researchers
- Principal investigator: Bagley, Kenneth C — Orlance, INC.
- Study coordinator: Bagley, Kenneth C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.